The Effect of Hemodialysis on Cardiac Biomarker Levels
-
Published:2022-12-31
Issue:2
Volume:16
Page:143-152
-
ISSN:2312-5365
-
Container-title:Libyan Journal of Medical Research
-
language:
-
Short-container-title:LJMR
Author:
Jaber Zaed Mohamed,Irqayah Naser Mohammed
Abstract
Background: According to the United States Renal Data System (USRD), the 2013 Annual Data Report indicates that patients with chronic kidney disease (CKD) have higher rates of congestive heart failure, acute myocardial infraction (MI), and cerebral vascular accidents compared to non-CKD patients. Aim of the Study: This study aimed to investigate the effects of the hemodialysis process on cardiac biomarker levels in hemodialysis patients. Method: A prospective study was carried conducted at Emssalata central hospital's hemodialysis department. The study involved a total of 25 individuals, 15 males and 10 females who were undergoing dialysis. A chemistry analyzer was used to measure the serum troponin I (cTn-I), creatin phosphokinase (CPK), and creatine kinase-MB (CK-MB) iso-enzyme in hemodialysis (HD) patients before and after the dialysis process. Results: The results showed that total CPK, CK-MB, and cTn-I levels had no significant differences in CKD patients' pre and post-dialysis, with (p = 0.989, 0.586, and 0.284) respectively. Hemodialysis patients have none significantly higher CPK, CK-MB and cTn-I ratios after hemodialysis process when compared to the values determined to each marker before hemodialysis process. Conclusion: The dialysis process had no effect on the levels of cardiac biomarkers (CPK, CK-MB, and cTn-I) in hemodialysis patients. The cardiac biomarker in hemodialysis patients appears to be unaffected by age, gender, or dialysis duration
Publisher
Medical Research Center
Reference16 articles.
1. Eknoyan, G., Lameire, N., Barsoum, R., Eckardt, K. U., Levin, A., Levin, N., Locatelli, F., MacLeod, A., Vanholder, R., Walker, R., & Wang, H. (2004). The burden of kidney disease: improving global outcomes. Kidney international, 66(4), 1310–1314. 2. Barreto, F. C., Stinghen, A. E., de Oliveira, R. B., Franco, A. T., Moreno, A. N., Barreto, D. V., Pecoits-Filho, R., Drüeke, T. B., & Massy, Z. A. (2014). The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 36(2), 221–235. 3. Vassalotti, J. A., Centor, R., Turner, B. J., Greer, R. C., Choi, M., Sequist, T. D., & National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2016). Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. The American journal of medicine, 129(2), 153–162.e7. 4. Kalantar-Zadeh K & Amin AN (2012). Toward more Accurate Detection and Risk Stratification of Chronic Kidney Disease. JAMA. 307(18):1976-7. 5. Mallett, A., Patel, C., Salisbury, A., Wang, Z., Healy, H., & Hoy, W. (2014). The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet journal of rare diseases, 9, 98.
|
|